NLS Pharma came in first place for the Innovation Award, handed out by the French consulting firm Universal Biotech. The prize, now in its ninth year, rewards the most promising startups (less than eight years old) and best academic research terms that are developing cutting edge projects in the area of life sciences. Close to 300 companies from around the world participated in this year’s competition, and the prize was handed out last week in Paris.
NLS Pharma took first place for its advances and cutting-edge progress with its NLS-1 compound, which is used in the treatment of attention deficit hyperactivity disorder (ADHD). The company announced in May of this year positive clinical data from a Phase 2 study of NLS-1, which showed that over half of the patients taking the compound experienced a more than 50 per cent reduction in symptoms, compared to the placebo group.
“These data are remarkable, and especially striking because NLS-1 is not classified as a stimulant,” said Tim Wigal, coordinating investigator for the study. “Should a pivotal trial deliver a replication of these results, NLS-1, if approved, may be a significant advance in ADHD treatment.”
Founded in 2015, NLS Pharma is headquartered in Stans. The privately owned biotech company focuses on the development of first-in-class treatments for ADHD, sleep disorders, cognitive impairment and other neurological disorders that remain largely under-diagnosed and for which unmet medical needs are significant.